PARTNER-2A 研究中 937 例中危患者行外科主动脉瓣置换术的结局
PARTNER-2A 随机试验中 937 例中危重度主动脉瓣狭窄患者于 57 个中心接受外科主动脉瓣置换术,平均年龄 82±6.7 岁,55% 为男性,2 年随访完成率 94%。手术死亡率为 4.1%(38 例,STS 预测风险 5.2%±2.3%),观察值与预期值比(O/E)为 0.8,院内卒中发生率为 5.4%(51 例),为预期的两倍。严重人工瓣膜-患者不匹配(260 例,33%)患者与非不匹配患者生存率相似(p>0.9)。
要点
- 中危患者行 SAVR 的 2 年结果优异,手术死亡率 4.1%,O/E 比为 0.8。
- 院内卒中发生率 5.4%(51 例),为预期的两倍,可能归因于术后强制神经学评估。
- 严重人工瓣膜-患者不匹配(33%)与无匹配患者生存率相似(p>0.9),2 年随访未发现明显结构性瓣膜退化。
核心结论
- 在这项经裁定的事件委员会审核的前瞻性研究中,中危患者行 SAVR 在 2 年时结果优异。
- 院内卒中多于预期,最可能归因于术后强制神经学评估。
- 2 年随访期间未发现明显的结构性瓣膜退化。
- 继续长期监测仍然重要。
研究设计与样本
- PARTNER-2A 随机试验中,2012 年 1 月至 2014 年 1 月间 57 个中心共 937 例中危重度主动脉瓣狭窄患者接受 SAVR。
- 平均年龄 82±6.7 岁,55% 为男性;140 例(15%)行微创手术,198 例(21%)行同期手术。
- 主要结局和超声心动图由独立事件委员会裁定,2 年随访完成率 94%。
主要发现
- 手术死亡率为 4.1%(38 例),STS 预测死亡风险为 5.2%±2.3%,观察值与预期值比(O/E)为 0.8。
- 院内卒中发生率为 5.4%(51 例),为预期的两倍。
- 主动脉阻断时间和体外循环时间分别为 75±30 分钟和 104±46 分钟。
- 严重人工瓣膜-患者不匹配患者(260 例,33%)与无严重不匹配患者生存率相似(p>0.9);行微创 SAVR 患者与常规手术患者生存率亦相似(p=0.3)。
- 死亡危险因素包括:恶病质(p=0.004)、三尖瓣反流(p=0.01)、冠心病(p=0.02)、术前心房颤动(p=0.001)、较高白细胞计数(p<0.0001)和较低血红蛋白(p=0.0002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Placement of Aortic Transcatheter Valves 2A (PARTNER-2A) randomized trial compared outcomes of transfemoral transcatheter and surgical aortic valve replacement (SAVR) in intermediate-risk patients with severe aortic stenosis. The purpose of the present study was to perform an in-depth analysis of outcomes after SAVR in the PARTNER-2A trial. METHODS: From January 2012 to January 2014, 937 patients underwent SAVR at 57 centers. Mean age was 82 ± 6.7 years and 55% were men. Less-invasive operations were performed in 140 patients (15%) and concomitant procedures in 198 patients (21%). Major outcomes and echocardiograms were adjudicated by an independent events committee. Follow-up was 94% complete to 2 years. RESULTS: Operative mortality was 4.1% (n = 38, Society of Thoracic Surgeons predicted risk of mortality: 5.2% ± 2.3%), observed to expected ratio (O/E) was 0.8, and in-hospital stroke was 5.4% (n = 51), twice expected. Aortic clamp and bypass times were 75 ± 30 minutes and 104 ± 46 minutes, respectively. Patients having severe prosthesis-patient mismatch (n = 260, 33%) had similar survival to patients without (p > 0.9), as did patients undergoing less-invasive SAVR (p = 0.3). Risk factors for death included cachexia (p = 0.004), tricuspid regurgitation (p = 0.01), coronary artery disease (p = 0.02), preoperative atrial fibrillation (p = 0.001), higher white blood cell count (p < 0.0001), and lower hemoglobin (p = 0.0002). CONCLUSIONS: In this adjudicated prospective study, SAVR in intermediate-risk patients had excellent results at 2 years. However, there were more in-hospital strokes than expected, most likely attributable to mandatory neurologic assessment after the procedure. No pronounced structural valve deterioration was found during 2-year follow-up. Continued long-term surveillance remains important.
引用
- Thourani VH, Forcillo J, Szeto WY, et al. Outcomes in 937 Intermediate-Risk Patients Undergoing Surgical Aortic Valve Replacement in PARTNER-2A. Ann Thorac Surg. 2017. PMID: 29253463. doi:10.1016/j.athoracsur.2017.10.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。